← Eichor
Study identifier: NCT07472803 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Longitudinal Body Composition Assessment in Breast Cancer Patients

Condition: Breast Neoplasms · Body Composition · Sarcopenia  ·  Sponsor: Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation

PhaseN/A
Planned participants100
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersNo

About this study

This observational cohort study aims to track longitudinal changes in body composition, including skeletal muscle mass and fat distribution, in patients diagnosed with breast cancer. Following primary surgery and adjuvant therapy, participants will be monitored over a 2-year period. The primary objective is to evaluate the natural progression of skeletal muscle mass index (SMI) and metabolic changes in this population. By conducting serial measurements, this study seeks to characterize the longitudinal trends in muscle loss and body composition shifts post-treatment, providing data to better understand the physiological impact of the cancer recovery process.

This description comes directly from the study's public registry record.

Talk to the study team

Valeria Chiu, Attending Physician  ·  +886266289779  ·  haydenbell28@gmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical FoundationNew Taipei City, Xindian Dist, TaiwanRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07472803